Development
Vera Therapeutics, Inc.
VERA
$20.64
$0.190.93%
NASDAQ
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 5.66M | 5.74M | 6.15M | 6.91M | 5.59M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 21.76M | 21.97M | 31.26M | 33.58M | 25.24M |
| Operating Income | -21.76M | -21.97M | -31.26M | -33.58M | -25.24M |
| Income Before Tax | -20.10M | -20.16M | -30.07M | -32.44M | -24.68M |
| Income Tax Expenses | -- | -- | -- | 1.00K | -- |
| Earnings from Continuing Operations | -20.10M | -20.16M | -30.07M | -32.44M | -24.68M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -20.10M | -20.16M | -30.07M | -32.44M | -24.68M |
| EBIT | -21.76M | -21.97M | -31.26M | -33.58M | -25.24M |
| EBITDA | -- | -- | -- | -33.54M | -25.20M |
| EPS Basic | -0.45 | -0.46 | -0.80 | -1.17 | -0.91 |
| Normalized Basic EPS | -0.28 | -0.28 | -0.50 | -0.73 | -0.56 |
| EPS Diluted | -0.45 | -0.46 | -0.80 | -1.17 | -0.91 |
| Normalized Diluted EPS | -0.28 | -0.28 | -0.50 | -0.73 | -0.56 |
| Average Basic Shares Outstanding | 44.36M | 44.27M | 37.67M | 27.73M | 27.22M |
| Average Diluted Shares Outstanding | 44.36M | 44.27M | 37.67M | 27.73M | 27.22M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |